Search

Displaying results 5351 - 5360 of 7186 in total
  1. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

  2. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  3. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

  4. Drug

    Telazorlimab

    go.drugbank.com/drugs/DB16374
    Investigational

    Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).

  5. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  6. Drug

    Duvakitug

    go.drugbank.com/drugs/DB19444
    Investigational

    Duvakitug is under investigation in clinical trial NCT05668013 (A Study to Evaluate the Long-term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease).

  7. Drug

    Zinpentraxin alfa

    go.drugbank.com/drugs/DB14852
    Investigational

    Zinpentraxin alfa is a recombinant form of PTX-2, a naturally circulating human protein.

  8. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

  9. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

    Synonyms: 5-[5-[(Z)-[3-(4-bromophenyl)-2-imino-4-oxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]isoindole-1,3-dione
  10. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.